Abstract:OBJECTIVES:There are clinical reports of nerve injury caused by ropivacaine. The mechanism for nerve injury induced by ropivacaine has not been fully clarified. This study aims to investigate the changes of pain threshold and L3 spinal cord genomics at 6 h and 24 h after intrathecal injection of 0.5% and 1.0% ropivacaine, and to explore the underlying mechanisms for nerve injury caused by ropivacaine.METHODS:A total of 30 male Sprague Dawley rats weighing 220-260 g were successfully implanted with microspinal catheter. The rats were randomly divided into 5 groups (each n=6): a control group (given saline), a ropivacaine group 1 and a ropivacaine group 2 (both given 1% ropivacaine), a ropivacaine group 3 and a ropivacaine group 4 (both given 0.5% ropivacaine). The rats received continuous intrathecal injection of corresponding drugs at 8.3 μL/h for 24 h via an implanted intrathecal catheter followed by 24 h-pause of injection for the ropivacaine group 2, the ropivacaine group 4 and the control group, 6 h-pause of injection for the ropivacaine group 1 and the ropivacaine group 3. For each group, the observation of behavioral change and the paw withdrawal mechanical threshold (PWMT) was conducted immediately after the injection and again after the pause of injection. After the PWMT observation, the rats were dissected to acquire L3 spinal cords. Illumina sequencing was applied to construct gene libraries. Then the statistical methods were used to find out differentially expressed genes between the groups. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway analysis were conducted for those genes. Real-time RT-PCR was used to determine different expressions of some of those genes.RESULTS:Compared with control group, the PWMT got higher in the ropivacaine group 1-4 and was positively correlated with concentration, negatively correlated with discontinuation duration. Compared with control group, the ropivacaine group 1 had 488 differentially expressed genes, of which 456 were up-regulated and 32 were down-regulated; the ropivacaine group 2 had 1 194 differentially expressed genes, of which 1 092 were up-regulated and 102 were down-regulated; the ropivacaine group 3 had 518 differentially expressed genes, of which 384 were up-regulated and 134 were down-regulated; and the ropivacaine group 4 had 68 differentially expressed genes, of which 46 were up-regulated and 22 were down-regulated. GO enrichment analysis and KEGG signaling pathway analysis showed that most of these differentially expressed genes were related to signaling pathways of inflammatory response.CONCLUSIONS:After intrathecal injection of 0.5% ropivacaine and 1.0% ropivacaine for 24 h, the differentially expressed genes in L3 spinal cord of rats are mainly related to signaling pathways of inflammatory response.

Inhibition of CD38/Cyclic ADP-ribose Pathway Protects Rats Against Ropivacaine-induced Convulsion

Abstract T P84: Neuroprotective Effect of Probenecid in a Rat Model of Transient Global Cerebral Ischemia-Reperfusion

Repeated Intrathecal Administration of Ropivacaine Causes Neurotoxicity in Rats

Inhibition of the glutamatergic PVT-NAc projections attenuates local anesthetic-induced neurotoxic behaviors

Naloxone Attenuates Ischemic Brain Injury in Rats Through Suppressing the NIK/IKKα/NF-κB and Neuronal Apoptotic Pathways.

[Behavioral and Ultrastructural Changes of Intrathecal Administered Ropivacaine in Spinal Cord of Rats].

Role of oxidative stress in spinal neurotoxicity induced by ropivacaine in rats

[Protective Effects of Pretreatment with Neurotrophin-3 on Intrathecal Ropivacaine in Rats].

Effects of Intrathecal Injection of Ropivacaine on Spinal Cord in Rats Based on Genomics.

The inhibition of sodim channel currents in rat sympathetic ganglion neurons by ropivacaine

Dexmedetomidine Dose-Dependently Attenuates Ropivacaine-Induced Seizures and Negative Emotions Via Inhibiting Phosphorylation of Amygdala Extracellular Signal-Regulated Kinase in Mice

Changes in expression of Bax and Bcl-2 in spinal cord in rats during neurotoxicity induced by rapivacaine

Ropivacaine-induced seizures evoked pain sensitization in rats: Participation of 5-HT/5-HT3R

Inhibition of P2X7 Receptor Ameliorates Transient Global Cerebral Ischemia/reperfusion Injury Via Modulating Inflammatory Responses in the Rat Hippocampus

Osthole-Mediated Inhibition of Neurotoxicity Induced by Ropivacaine via Amplification of the Cyclic Adenosine Monophosphate Signaling Pathway

Roles of CaMKIIβ in the Neurotoxicity Induced by Ropivacaine Hydrochloride in Dorsal Root Ganglion.

Activation of the Akt Attenuates Ropivacaine-Induced Myelination Impairment in Spinal Cord and Sensory Dysfunction in Neonatal Rats

Dexmedetomidine pretreatment alleviates ropivacaine-induced neurotoxicity via the miR-10b-5p/BDNF axis

Inhibiting the CD38/cADPR Pathway Protected Rats Against Sepsis Associated Brain Injury

In Vivo and in Vitro Evidence of the Neurotoxic Effects of Ropivacaine: the Role of the Akt Signaling Pathway.